Schedule I - Parent Company Condensed Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net loss	$ (66,483)	$ (84,473)	$ (19,640)	$ (18,267)	$ (85,231)	$ (86,091)	$ (101,650)	$ (55,433)	$ (188,863)	$ (328,405)	$ (30,143)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest									2,750	2,750	9,389
Amortization of debt discount and debt issuance costs									1,222	1,161	785
Losses from investments in investees									107	383	629
Share-Based Payment Arrangement, Noncash Expense									11,413	18,509	13,632
Non-cash revenue from the transfer of intellectual property									0	0	(3,801)
Realized gain on equity securities and disposal of fixed assets									1,321	(455)	(33,922)
Loss on conversion of the 2025 Notes									0	0	11,111
Gain on sale of GeneDx									0	(18,559)	0
Net cash (used in) provided by operating activities									(28,197)	(95,189)	38,337
Cash flows from investing activities:
Investments in investees									(5,000)	0	(2,000)
Net cash (used in) provided by investing activities									(18,198)	91,038	35,949
Cash flows from financing activities:
Redemption of 2033 Senior Notes									(3,000)	0	0
Net cash (used in) provided by financing activities									(11,303)	22,971	(10,350)
Net increase (decrease) in cash and cash equivalents									(57,310)	18,481	62,499
Cash and cash equivalents at beginning of period				153,191				134,710	153,191	134,710	72,211
Cash and cash equivalents at end of period	95,881				153,191				95,881	153,191	134,710
SUPPLEMENTAL INFORMATION:
Interest paid									8,135	7,420	8,515
Income taxes paid, net of refunds									3,712	8,037	5,969
Parent Company [Member]
Net loss									(188,863)	(328,405)	(30,143)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest									2,750	2,750	9,389
Amortization of debt discount and debt issuance costs									1,154	1,093	722
Losses from investments in investees									107	383	629
(Income) loss from subsidiaries									110,953	126,425	(70,313)
Share-Based Payment Arrangement, Noncash Expense									11,414	18,509	13,632
Non-cash revenue from the transfer of intellectual property									0	0	(3,801)
Realized gain on equity securities and disposal of fixed assets									(364)	0	(2,981)
Change in fair value of derivative instruments and equity securities									16,891	154,473	4,871
Loss on conversion of the 2025 Notes									0	0	11,111
Gain on sale of GeneDx									0	(18,559)	0
Changes in other assets and liabilities									11,559	(14,993)	10,970
Net cash (used in) provided by operating activities									(34,399)	(58,324)	(55,914)
Cash flows from investing activities:
Investments in investees									(5,000)	0	(2,000)
Subsidiary financing									(30,242)	23,866	69,608
Proceeds from sale of investments									364	0	0
Proceeds from sale of equity securities									0	115,423	8,078
Net cash (used in) provided by investing activities									(34,878)	139,289	75,686
Cash flows from financing activities:
Proceeds from the exercise of Common Stock options and warrants									(272)	(774)	1,080
Redemption of 2033 Senior Notes									(3,000)	0	0
Net cash (used in) provided by financing activities									(3,272)	(774)	1,080
Net increase (decrease) in cash and cash equivalents									(72,549)	80,191	20,852
Cash and cash equivalents at beginning of period				$ 104,783				$ 24,592	104,783	24,592	3,740
Cash and cash equivalents at end of period	32,234				104,783				32,234	104,783	24,592
SUPPLEMENTAL INFORMATION:
Interest paid									8,135	7,420	8,515
Income taxes paid, net of refunds									3,712	8,037	5,969
Non-cash financing:
Common Stock options and warrants, surrendered in net exercise	$ 301				$ 1,268				301	1,268	0
Issuance of common stock for acquisition of ModeX									0	221,662	0
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable									$ 6,689	$ 172,000	$ 0